CAS 9005-79-2|Glycogen
| Common Name | Glycogen | ||
|---|---|---|---|
| CAS Number | 9005-79-2 | Molecular Weight | 666.57800 |
| Density | 1.83g/cm3 | Boiling Point | 1027.2ºC at 760mmHg |
| Molecular Formula | C24H42O21 | Melting Point | 270-280 °C (dec.) |
| MSDS | ChineseUSA | Flash Point | 575ºC |
Names
| Name | (2S,3R,4S,5S,6R)-2-[[(2R,3S,4R,5R,6R)-4,5-dihydroxy-3-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[(2R,3S,4R,5R,6S)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol |
|---|---|
| Synonym | More Synonyms |
Glycogen BiologicalActivity
| Description | Glycogen is a glycolytic intermediates and high-energy phosphates that can serve as a form of energy storage in humans, animals, fungi, and bacteria. |
|---|---|
| Related Catalog | Natural Products >>OthersResearch Areas >>Metabolic Disease |
| Target | Human Endogenous Metabolite |
| References | [1]. Harris RC, et al. Glycogen, glycolytic intermediates and high-energy phosphates determined in biopsy samples of musculus quadriceps femoris of man at rest. Methods and variance of values. Scand J Clin Lab Invest. 1974 Apr;33(2):109-20. |
Chemical & Physical Properties
| Density | 1.83g/cm3 |
|---|---|
| Boiling Point | 1027.2ºC at 760mmHg |
| Melting Point | 270-280 °C (dec.) |
| Molecular Formula | C24H42O21 |
| Molecular Weight | 666.57800 |
| Flash Point | 575ºC |
| Exact Mass | 666.22200 |
| PSA | 347.83000 |
| Index of Refraction | 1.687 |
| InChIKey | BYSGBSNPRWKUQH-QUMRWLSBSA-N |
| SMILES | OCC1OC(OCC2OC(OC3C(CO)OC(O)C(O)C3O)C(O)C(O)C2OC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O |
| Storage condition | 2-8°C |
| Water Solubility | H2O: 20 mg/mL, clear to hazy, faintly yellow |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intrauterine
- DOSE :
- 20 mg/kg
- SEX/DURATION :
- female 2 day(s) after conception
- TOXIC EFFECTS :
- Reproductive - Maternal Effects - uterus, cervix, vagina Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea)
- REFERENCE :
- SCYYDZ Shengzhi Yu Biyun. Reproduction and Contraception. (China International Book Trading Corp., POB 2820, Beijing, Peop. Rep. China) 1980- Volume(issue)/page/year: 11(4),7,1991 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X3656 No. of Facilities: 16 (estimated) No. of Industries: 1 No. of Occupations: 2 No. of Employees: 362 (estimated) No. of Female Employees: 306 (estimated)
Safety Information
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| Hazard Codes | Xi |
| Risk Phrases | 36/37/38 |
| Safety Phrases | S24/25-S26 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
| RTECS | MC2700000 |
Articles100
More Articles| Spermidine feeding decreases age-related locomotor activity loss and induces changes in lipid composition. PLoS ONE 9(7) , e102435, (2014) Spermidine is a natural polyamine involved in many important cellular functions, whose supplementation in food or water increases life span and stress resistance in several model organisms. In this wo... | |
| Non-muscle involvement in late-onset glycogenosis II. Acta Myol. 32(2) , 91-4, (2013) Glycogenosis II (GSD II) is an autosomal recessive lysosomal storage disorder resulting from acid alpha-glucosidase deficiency, subsequent accumulation of glycogen in tissues, impairment of autophagic... | |
| Clinical features of Pompe disease. Acta Myol. 32(2) , 82-4, (2013) Glycogen storage disease type II - also called Pompe disease or acid maltase deficiency - is an autosomal recessive metabolic disorder, caused by an accumulation of glycogen in the lysosome due to def... |
Synonyms
| Lyoglycogen |
| GLYCOGEN |
| Animal starch |
| Phytoglycogen |
| EINECS 232-683-8 |
| Liver starch |
| MFCD00081547 |
